A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

March 21, 2026

Study Completion Date

May 16, 2027

Conditions

Eosinophilic Granulomatosis With Polyangiitis

Interventions

DRUG

SHR-1703

SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.

DRUG

SHR-1703 Placebo

SHR-1703 Placebo will be administered by Subcutaneous injection in Phase 3.

Trial Locations (2)

RECRUITING

Beijing Hospital, Beijing

RECRUITING

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY